• Home
  1. Home
  2. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research
Scientific article
Review
OA Policy
English

Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research

ContributorsKerschbaumer, Andreas; Smolen, Josef S; Nash, Peter; Doerner, Thomas; Dougados, Maxime; Fleischmann, Roy; Geissler, Klaus; McInnes, Iain B; Takeuchi, Tsutomu; Trauner, Michael; Winthrop, Kevin; de Wit, Maarten; Boehncke, Wolf-Henning; Falzon, Louise; van der Heijde, Desirée
Published inRMD Open, vol. 6, no. 3
Publication date2020
Abstract

Review of efficacy and safety of Janus kinase (JAK) inhibition in immune-mediated inflammatory diseases (IMIDs).

Keywords
  • Arthritis
  • Ankylosing
  • Lupus erythematosus
  • Psoriatic
  • Rheumatoid
  • Spondylitis
  • Systemic
Affiliation entities
Research groups
Citation (ISO format)
KERSCHBAUMER, Andreas et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research. In: RMD Open, 2020, vol. 6, n° 3. doi: 10.1136/rmdopen-2020-001374
Main files (1)
Article (Published version)
accessLevelPublic CC BY-NC
Identifiers
Additional URL for this publicationhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7856126/
Journal ISSN2056-5933
180views
175downloads

Technical informations

Creation30/04/2021 15:29:00
First validation30/04/2021 15:29:00
Update24/01/2025 15:50:38
Status update24/01/2025 15:50:38
Last indexation24/01/2025 15:58:44
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack